Skip to main content


Fig. 3 | Molecular Cancer

Fig. 3

From: LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/β-catenin pathway

Fig. 3

LINC01133 inhibits proliferation, migration and EMT in vitro and in vivo. a Relative expression of LINC01133 confirmed by qRT-PCR in SGC-7901 and HGC-27 cells with LINC01133 overexpression. b, c Proliferation and migration assays of SGC-7901 and HGC-27 cells with LINC01133 overexpression by the CCK-8 assay (b), and transwell assay (c). d Immunoblot assay to evaluate the expression of vimentin, E-cadherin, and N-cadherin proteins in AGS and BGC-823 cells after LINC01133 knockdown or in SGC-7901 cells after LINC01133 overexpression. The reference protein GAPDH was used as an internal control. Numbers shows the ratio of target protein/GAPDH (arbitrary unit). e The right armpit was injected with SGC-7901 cells transfected with LINC01133 expression vector or empty vector in upper panel. Representative images of xenograft tumors are indicated in the bottom panel. f, g Tumor volume and weight of the xenograft in LINC01133 overexpression groups and control group. h Left panel: representative images of lung metastatic nodules of LINC01133 overexpression groups and control group are indicated by blue arrows. Representative hematoxylin and eosin (H&E) staining results of corresponding lung metastatic nodules are shown in right panel. i Statistical analysis of numbers of metastatic nodules in the lung. Error bars: mean ± SD from three independent experiments. *P <  0.05 and **P <  0.01

Back to article page